Comparative Pharmacology
Head-to-head clinical analysis: SULFISOXAZOLE versus SULSOXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFISOXAZOLE versus SULSOXIN.
SULFISOXAZOLE vs SULSOXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfisoxazole is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking the synthesis of dihydrofolic acid and ultimately inhibiting bacterial folate synthesis and DNA replication.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs) and disrupting peptidoglycan cross-linking.
1-2 g orally once, then 500 mg-1 g orally every 4-6 hours; maximum 6 g/day.
500 mg orally 4 times daily for 10-14 days (or 1 g orally 4 times daily for severe infections).
None Documented
None Documented
Terminal elimination half-life is 5-7 hours in adults with normal renal function; prolonged to 12-20 hours in renal impairment (CrCl <30 mL/min).
Clinical Note
moderateSulfisoxazole + Gatifloxacin
"Sulfisoxazole may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSulfisoxazole + Rosoxacin
"Sulfisoxazole may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSulfisoxazole + Trovafloxacin
"Sulfisoxazole may increase the hypoglycemic activities of Trovafloxacin."
Clinical Note
moderateSulfisoxazole + Nalidixic acid
8 hours (terminal) — extends in renal impairment (up to 24 hours in CrCl <30 mL/min); requires dose adjustment
Renal excretion accounts for 70-85% of elimination, predominantly as unchanged drug (30-50%) and the N4-acetyl metabolite (15-30%). Biliary/fecal excretion is minimal (<5%).
Renal: 70% (unchanged); biliary/fecal: 20%; minor hepatic metabolism (<10%)
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic
"Sulfisoxazole may increase the hypoglycemic activities of Nalidixic acid."